Two dimensional images of a person implicitly contain several useful biometric information such as gender, iris colour, weight, etc. Among them, body weight is a useful metric for a number of usecases such as forensics, fitness and health analysis, airport dynamic luggage allowance, etc. Most current solutions for body weight estimation from images make use of additional apparatus like depth sensors and thermal cameras along with predefined features such as gender and height which generally make them more computationally intensive. Motivated by the need to provide a time and cost efficient solution, a novel computer-vision based method for body weight estimation using only 2D images of people is proposed. Considering the anthropometric features from the two most common types of images, facial and full body, facial landmark measurements and body joint measurements are used in deep learning and XG boost regression models to estimate the person's body weight. The results obtained, though comparable to previous approaches, perform much faster due to the reduced complexities of the proposed models, with facial models performing better than full body models.
Aims:To find out the pharmacokinetic and pharmacodynamic drug interaction of carbamazepine, a protype drug used to treat painful diabetic neuropathy with glibenclamide in healthy albino Wistar rats following single and multiple dosage treatment.Materials and Methods:Therapeutic doses (TD) of glibenclamide and TD of carbamazepine were administered to the animals. The blood glucose levels were estimated by GOD/POD method and the plasma glibenclamide concentrations were estimated by a sensitive RP HPLC method to calculate pharmacokinetic parameters.Results:In single dose study the percentage reduction of blood glucose levels and glibenclamide concentrations of rats treated with both carbamazepine and glibenclamide were significantly increased when compared with glibenclamide alone treated rats and the mechanism behind this interaction may be due to inhibition of P-glycoprotein mediated transport of glibenclamide by carbamazepine, but in multiple dose study the percentage reduction of blood glucose levels and glibenclamide concentrations were reduced and it may be due to inhibition of P-glycoprotein mediated transport and induction of CYP2C9, the enzyme through which glibenclamide is metabolised.Conclusions:In the present study there is a pharmacokinetic and pharmacodynamic interaction between carbamazepine and glibenclamide was observed. The possible interaction involves both P-gp and CYP enzymes. To investigate this type of interactions pre-clinically are helpful to avoid drug-drug interactions in clinical situation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.